Budesonide Suspension
Product Images NDC 0093-6815

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Budesonide (NDC 0093-6815). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Teva Pharmaceuticals Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image 1

Chemical structure diagram showing the molecular formula C25H34O6 and molecular weight 430.5 of budesonide, the active ingredient in the product Budesonide inhalation suspension by Teva Pharmaceuticals USA, Inc.*

FDA Label Image

Budesonide Inhalation Suspension 0.5 mg/2 mL, 30s (6 Pouches Of Five 2 mL Vials Each) Carton, Part 1 Of 2 (Image 10)

Carton label for Budesonide Inhalation Suspension 0.5 mg/2 mL by Teva Pharmaceuticals USA, Inc. The package includes 6 pouches of five 2 mL vials each (30 unit-dose vials). Instructions for use and storage details are printed on the carton, along with inactive ingredients and manufacturer information. The label specifies the medication is for oral inhalation use only and not for injection.*

FDA Label Image

Image 2

A line graph displaying mean change from baseline nighttime asthma symptoms over time, from baseline to 12 weeks. The graph compares results for placebo and three dosages of Budesonide suspension (0.25 mg, 0.5 mg, and 1.0 mg once daily). Each treatment group is represented by a distinct marker. The x-axis shows time intervals in weeks, and the y-axis represents change in nighttime symptoms.*

FDA Label Image

Image 3

A line graph comparing mean change from baseline in nighttime asthma symptoms over 12 weeks among three groups: placebo, 0.25 mg twice daily Budesonide, and 0.5 mg twice daily Budesonide. The x-axis shows time intervals from baseline to weeks 0-12, and the y-axis measures symptom change. Both Budesonide doses show greater symptom reduction than placebo, with statistical p-values of 0.022 and 0.021 respectively.*

FDA Label Image

Image 4

A line graph depicting mean change from baseline in nighttime asthma symptoms over 12 weeks. The x-axis represents study weeks subdivided into intervals, and the y-axis shows mean change in symptom scores. Lines compare placebo, 0.25 mg twice daily, and 0.5 mg twice daily dosages of Budesonide suspension for inhalation. A legend differentiates the three groups, and p-values for dosages are noted below the graph.*

FDA Label Image

Image 5

An instructional illustration showing a person handling a blister pack, likely demonstrating how to remove a tablet or capsule from the packaging by pressing it through the foil backing. No specific drug information is visible in the image.*

FDA Label Image

Image 6

An instructional illustration showing a hand holding and rotating a small inhalation suspension vial or ampule, likely demonstrating preparation steps for use. The image is labeled as Figure 2 and is related to Budesonide inhalation suspension, a respiratory medication by Teva Pharmaceuticals USA, Inc.*

FDA Label Image

Image 7

An instructional illustration showing a hand holding a small vial or ampule and another hand using a dropper or pipette to extract liquid from it. The image is labeled 'Figure 3' and likely demonstrates a step in preparing or administering the Budesonide suspension for inhalation.*

FDA Label Image

Image 8

An instructional illustration showing a person pressing the tip of an inhalation suspension bottle, dispensing the medication into a hand. The image demonstrates the proper technique for using Budesonide inhalation suspension.*

FDA Label Image

Image 9

Packaging label for Budesonide Inhalation Suspension 0.25 mg/2 mL by Teva Pharmaceuticals USA, Inc. The carton holds 6 pouches of five 2 mL unit-dose vials (30 unit-dose vials total). This respiratory inhalation suspension is labeled for oral inhalation use only and not for injection, featuring patient instructions and storage guidance. Manufactured in England by Norton Healthcare Limited.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.